In March 2025, the company introduced new programs for the direct-to-buyer offering of its Wegovy weight loss drug. The company established a different pharmacy, referred to as NovoCare, which would cost consumers $499 every month for usage of the drug, under 50 percent the price of the drug by way of other pharmaceutical distribution networks.[fif